Literature DB >> 28262115

Classification of natural products as sources of drugs according to the biopharmaceutics drug disposition classification system (BDDCS).

Ji Li1, Caroline A Larregieu2, Leslie Z Benet3.   

Abstract

Natural products (NPs) are compounds that are derived from natural sources such as plants, animals, and micro-organisms. Therapeutics has benefited from numerous drug classes derived from natural product sources. The Biopharmaceutics Drug Disposition Classification System (BDDCS) was proposed to serve as a basis for predicting the importance of transporters and enzymes in determining drug bioavailability and disposition. It categorizes drugs into one of four biopharmaceutical classes according to their water solubility and extent of metabolism. The present paper reviews 109 drugs from natural product sources: 29% belong to class 1 (high solubility, extensive metabolism), 22% to class 2 (low solubility, extensive metabolism), 40% to class 3 (high solubility, poor metabolism), and 9% to class 4 (low solubility, poor metabolism). Herein we evaluated the characteristics of NPs in terms of BDDCS class for all 109 drugs as wells as for subsets of NPs drugs derived from plant sources as antibiotics. In the 109 NPs drugs, we compiled 32 drugs from plants, 50% (16) of total in class 1, 22% (7) in class 2 and 28% (9) in class 3, none found in class 4; Meantime, the antibiotics were found 5 (16%) in class 2, 22 (71%) in class 3, and 4 (13%) in class 4; no drug was found in class 1. Based on this classification, we anticipate BDDCS to serve as a useful adjunct in evaluating the potential characteristics of new natural products.
Copyright © 2016 China Pharmaceutical University. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biopharmaceutics Drug Disposition Classification System (BDDCS); Dose number; Natural products (NPs); Solubility and extent of metabolism

Mesh:

Substances:

Year:  2016        PMID: 28262115     DOI: 10.1016/S1875-5364(17)30013-4

Source DB:  PubMed          Journal:  Chin J Nat Med        ISSN: 1875-5364


  6 in total

1.  Drug development: Lessons from nature.

Authors:  Sunil Mathur; Clare Hoskins
Journal:  Biomed Rep       Date:  2017-05-09

Review 2.  Challenges in working towards an internal threshold of toxicological concern (iTTC) for use in the safety assessment of cosmetics: Discussions from the Cosmetics Europe iTTC Working Group workshop.

Authors:  Corie A Ellison; Karen L Blackburn; Paul L Carmichael; Harvey J Clewell; Mark T D Cronin; Bertrand Desprez; Sylvia E Escher; Steve S Ferguson; Sébastien Grégoire; Nicola J Hewitt; Heli M Hollnagel; Martina Klaric; Atish Patel; Sabrina Salhi; Andreas Schepky; Barbara G Schmitt; John F Wambaugh; Andrew Worth
Journal:  Regul Toxicol Pharmacol       Date:  2019-01-15       Impact factor: 3.271

3.  Cytotoxic and chemosensitizing effects of glycoalkaloidic extract on 2D and 3D models using RT4 and patient derived xenografts bladder cancer cells.

Authors:  Mariza Abreu Miranda; Priscyla Daniely Marcato; Arindam Mondal; Nusrat Chowdhury; Aragaw Gebeyehu; Sunil Kumar Surapaneni; Maria Vitória Lopes Badra Bentley; Robson Amaral; Chong-Xian Pan; Mandip Singh
Journal:  Mater Sci Eng C Mater Biol Appl       Date:  2020-08-27       Impact factor: 7.328

Review 4.  Genetic Diversity in Drug Transporters: Impact in African Populations.

Authors:  Iris Rajman; Laura Knapp; Imad Hanna
Journal:  Clin Transl Sci       Date:  2020-03-31       Impact factor: 4.689

5.  Formulation and Characterization of Carbopol-934 Based Kojic Acid-Loaded Smart Nanocrystals: A Solubility Enhancement Approach.

Authors:  Barkat Ali Khan; Maryam Waheed; Khaled M Hosny; Waleed Y Rizg; Samar S Murshid; Majed Alharbi; Muhammad Khalid Khan
Journal:  Polymers (Basel)       Date:  2022-04-06       Impact factor: 4.329

6.  Redox-Responsive Disulfide Bond-Bridged mPEG-PBLA Prodrug Micelles for Enhanced Paclitaxel Biosafety and Antitumor Efficacy.

Authors:  Sheng Chang; Yanfei Wang; Tianyi Zhang; Xiaohui Pu; Lanlan Zong; Heyun Zhu; Luling Zhao; Bo Feng
Journal:  Front Oncol       Date:  2019-08-27       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.